Acute skin radiation toxicity seen with concurrent T-DM1: A single institutional report of 35 patients. (February 2023)

• Record Type: Journal Article
• Authors: Dastgheyb, Sana Sara; Kim, Kristine; Doucette, Abigail; Freedman, Gary; Shah, Payal; Makhlin, Igor; Clark, Amy; Taunk, Neil
• Is Part Of: Breast. Volume 67(2023)
• Page Start: 26
• Page End: 29
• Publication Date: 2023-02
• Subjects: Skin toxicity -- Concurrent chemo radiation -- Chemo-immunotherapy -- Adjuvant radiation; Breast -- Diseases -- Periodicals; Breast -- Tumors -- Periodicals; Breast -- Periodicals; Electronic journals; Periodicals; 616
• DOI: 10.1016/j.breast.2022.12.002
• Languages: English
• ISSNs: 0960-9776

Abstract

Abstract: Trastuzumab emtansine (T-DM1) is a novel therapeutic for HER2+ breast cancer patients with residual disease after neoadjuvant chemotherapy. Concurrent radiotherapy (RT) is offered to a subset of patients based on results from the KATHERINE trial which showed a favorable safety profile. With emerging therapies that necessitate concurrent RT, we must closely follow rates of skin toxicity. Our first 35 patients who underwent concurrent T-DM1 treatment with breast/chest wall (CW) ± nodal irradiation are reported. Most patients (22/35) had grade 2+ toxicity and 3 patients had grade 3 toxicities. We add our experience with radiation dermatitis and concurrent T-DM1 to contribute to existing reports.